Targeted, non-invasive brain stimulation has been shown to significantly improve symptoms of post-traumatic stress disorder (PTSD) by calming the brain’s fear center, with benefits lasting months after treatment. The findings, published in The American Journal of Psychiatry, highlight a promising advancement in PTSD therapy.
How Transcranial Magnetic Stimulation (TMS) Works
Transcranial magnetic stimulation (TMS) is an FDA-approved treatment for conditions including depression but has not yet been approved for PTSD. The technique uses magnetic pulses to influence activity in specific brain regions. PTSD is associated with heightened activity in the amygdala, the brain’s fear-processing center.
Study Design and Findings
A clinical trial conducted by researchers in the Emory University Department of Psychiatry and Behavioral Sciences investigated whether two weeks of low-frequency TMS could reduce amygdala reactivity to threats and improve PTSD symptoms. The study used MRI scans to precisely target stimulation, personalizing treatment for each participant.
Fifty adults with PTSD symptoms enrolled in the study, and 47 completed it. Most participants were recruited through the Grady Trauma Project, a large-scale clinical research initiative studying civilian trauma at Grady Health System and the Emory University School of Medicine.
Participants were randomly assigned to receive either active TMS or a placebo treatment in a blinded design. MRI scans measured amygdala responses to threats before and after treatment. The researchers found that active TMS reduced right amygdala reactivity to threats, and participants who received active TMS showed significant improvement in PTSD symptoms.
Clinical benefits were observed after just two weeks of treatment and lasted at least six months—the full duration examined in the study. Seventy-four percent of individuals in the active TMS group experienced clinically meaningful symptom reduction.
Expert Insights and Patient Experiences
“This study shows that we can directly target the brain circuits involved in PTSD and produce measurable changes in both brain function and symptoms. By using MRI to guide stimulation, we are moving toward more precise, individualized treatments that address the biology of the disorder.”
Unlike traditional talk therapy, TMS does not require patients to recount traumatic experiences, which may reduce barriers to care. Participants reported changes in how they emotionally experienced their trauma, including improved management of nightmares. Some described the treatment as “life changing,” saying it “gave me back my life.”
Significance and Future Directions
This is the first study to use MRI scans to individualize TMS for PTSD. By demonstrating a specific change in the amygdala—a region known to function differently in PTSD—the findings advance the understanding of PTSD neurobiology and suggest new treatment directions locally, nationally, and internationally.
The study was funded by the National Institutes of Health and the Brain and Behavior Research Foundation. Additional contributors include researchers from Emory University, Harvard Medical School, Wayne State University, Dartmouth College, and the National Center for PTSD.
The findings were published in The American Journal of Psychiatry.
Related articles
MIT Research Funding Drops 10% Amid Federal Cuts and Immigration Policy Changes
MIT President Sally Kornbluth said Thursday that the school’s research enterprise has shrunk 10 percent from a year ago and warned of a persistent dro...
Study Links High Air Pollution to Increased Post-Surgical Complications on Utah’s Wasatch Front
New research on Utah’s Wasatch Front—which occasionally experiences the worst air quality in the nation—has found an association between high air poll...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Science-Backed: 8,500 Steps Daily for Sustainable Weight Loss
A new study demonstrates that 8,500 daily steps is the sweet spot for weight management. Stewart Cohen/Getty Images Walking 8,500 steps per day can he...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up u...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...